Literature DB >> 33490356

Electrochemotherapy and basal cell carcinomas: First-time appraisal of the efficacy of electrochemotherapy on survivorship using FACE-Q.

Phoebe Lyons1, Alison Kennedy2, A James P Clover1,2.   

Abstract

INTRODUCTION: The establishment and success of new treatments are significantly influenced by patient satisfaction. Post-operative scarring is an important outcome for patients, and subsequently influences overall satisfaction with treatment. The objective was to measure post-treatment scarring satisfaction using a novel scale, the FACE-Q Skin Cancer Module, to compare electrochemotherapy (ECT) to traditional surgical excision (SE) to demonstrate equivalence of ECT and SE regarding outcome and survivorship. METHODS AND MATERIALS: This was a multicentre first-time appraisal study of the efficacy of ECT. All patients with facial BCCs treated with either ECT or SE were deemed eligible and subsequently recruited from either a previous clinical trial or outpatient clinics, respectively. Of the 40 participants invited, 25 responses were received. Patient information recorded included age, gender, location and size of BCCs, and time since treatment. Patient outcomes were measured using the FACE-Q Skin Cancer Module.
RESULTS: The ECT and SE groups consisted of 14 and 11 patients, respectively. Mean age was 68 years (M:F = 16:9), while mean time since treatment was 4.98 years (range 0.3-9.58 years). Appraisal of scars was significantly higher in the ECT cohort versus SE (p = 0.034). Cancer worry was equivalent across both cohorts (p = 0.804). According to treatment type, no correlation was detected between time since treatment and both appraisal of scars (ECT p = 0.466 and SE p = 0.214) and adverse effects (ECT p = 0.924 and SE p = 0.139).
CONCLUSION: Based on this study, ECT has superior scar outcomes and overall equivalence to SE. This demonstrates high patient satisfaction for those treated with ECT without any additional cancer worry.
© 2020 The Authors.

Entities:  

Keywords:  Basal cell carcinoma; Electrochemotherapy; FACE-Q; Survivorship

Year:  2020        PMID: 33490356      PMCID: PMC7809247          DOI: 10.1016/j.jpra.2020.12.004

Source DB:  PubMed          Journal:  JPRAS Open        ISSN: 2352-5878


  20 in total

1.  FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery.

Authors:  E H Lee; A F Klassen; S J Cano; K S Nehal; A L Pusic
Journal:  Br J Dermatol       Date:  2018-05-23       Impact factor: 9.302

Review 2.  Basal cell carcinoma-treatments for the commonest skin cancer.

Authors:  Carola Berking; Axel Hauschild; Oliver Kölbl; Gerson Mast; Ralf Gutzmer
Journal:  Dtsch Arztebl Int       Date:  2014-05-30       Impact factor: 5.594

3.  FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation.

Authors:  Anne F Klassen; Stefan J Cano; Jonathan A Schwitzer; Amie M Scott; Andrea L Pusic
Journal:  Plast Reconstr Surg       Date:  2015-02       Impact factor: 4.730

Review 4.  Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases.

Authors:  Julie Gehl; Gregor Sersa; Louise Wichmann Matthiessen; Tobian Muir; Declan Soden; Antonio Occhini; Pietro Quaglino; Pietro Curatolo; Luca G Campana; Christian Kunte; A James P Clover; Giulia Bertino; Victor Farricha; Joy Odili; Karin Dahlstrom; Marco Benazzo; Lluis M Mir
Journal:  Acta Oncol       Date:  2018-03-25       Impact factor: 4.089

Review 5.  Basal Cell Carcinoma Review.

Authors:  Dennis P Kim; Kylee J B Kus; Emily Ruiz
Journal:  Hematol Oncol Clin North Am       Date:  2019-02       Impact factor: 3.722

Review 6.  Skin cancer: an overview of epidemiology and risk factors.

Authors:  Randy Gordon
Journal:  Semin Oncol Nurs       Date:  2013-08       Impact factor: 2.315

Review 7.  Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review.

Authors:  Katsunori Fujii; Toshiyuki Miyashita
Journal:  Pediatr Int       Date:  2014-10       Impact factor: 1.524

8.  Measuring patient-reported outcomes in facial aesthetic patients: development of the FACE-Q.

Authors:  Anne F Klassen; Stefan J Cano; Amie Scott; Laura Snell; Andrea L Pusic
Journal:  Facial Plast Surg       Date:  2010-07-27       Impact factor: 1.446

9.  Electrochemotherapy for the treatment of ocular basal cell carcinoma; a novel adjunct in the disease management.

Authors:  S P Salwa; M G Bourke; P F Forde; M O'Shaughnessy; S T O'Sullivan; E J Kelly; D M Soden; A J P Clover
Journal:  J Plast Reconstr Aesthet Surg       Date:  2013-08-01       Impact factor: 2.740

10.  Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients.

Authors:  Andrea L Pusic; Anne F Klassen; Amie M Scott; Stefan J Cano
Journal:  Clin Plast Surg       Date:  2013-04       Impact factor: 2.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.